The first-in-ever CD33/CD3-targeted BiTE, called AMG330, prolonged the survival of human AML-transplanted immunodeficient mice [87] and has been tested in early phase trials (mentioned in a later chapter). Here, CD33 is linked to acute myeloid leukemia.